Identification of ISCA1 as novel immunological and prognostic biomarker for bladder cancer

被引:2
|
作者
Zhou, Renlong [1 ]
Peng, Naixiong [2 ]
Li, Wei [2 ]
机构
[1] Shenzhen Longhua Dist Cent Hosp, Dept Blood Transfus, Shenzhen, Peoples R China
[2] Shenzhen Longhua Dist Cent Hosp, Dept Urol, Shenzhen, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
pan-cancer; ISCA1; BLCA; GSEA; immune microenvironment; prognostic analysis; IMMUNE CHECKPOINT INHIBITORS; CELLS; CARCINOMA;
D O I
10.3389/fimmu.2022.975503
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundIron-sulfur cluster assembly 1 (ISCA1) has a significant effect on respiratory complexes and energy metabolism. Although there is some evidence that ISCA1 gene expression impacts energy metabolism and consequently has a role in tumorigenesis and cancer metastasis in different types of malignancies, no systematic pan-cancer study of the ISCA1 has been conducted. As a result, we sought to investigate ISCA1's predictive value in 33 cancer types as well as its possible immunological function. MethodsWe included the pan-cancer expression profile dataset and clinical data from the public database. Firstly, the single-sample Gene Set Enrichment Analysis (ssGSEa) approach was employed for analyzing the immune link in pan-cancer, while the limma package was utilized for analyzing the differential expression in cancer species. Subsequently, ciberport, MCP-counter, TIMER2, quanTIseq, and xCELL were employed for analyzing bladder cancer (BLCA)'s immune infiltration. Least absolute shrinkage and selection operator (Lasso) were employed for choosing the best gene to develop the immune risk scoring model. ResultsISCA1 gene expression was positively related to four immune signatures (chemokine, immunostimulator, MHC, and receptor) in BLCA. Samples of BLCA were sorted into two groups by the best cut-off of ISCA1 expression degree. The group with a high level of ISCA1 expression had a higher risk, suggesting that the ISCA1 gene was a risk factor in BLCA, and its high expression resulted in a poorer prognosis. Additionally, it was noted that ISCA1 was positively linked with these immune checkpoints. Moreover, there was a considerable positive link between ISCA1 and different immune properties in subgroups with different immune checkpoint inhibiting responses. Finally, an immune risk scoring model was made and it showed a better score in comparison to that of TIDE. ConclusionISCA1 can be a prognostic marker for a variety of cancers, particularly BLCA. Its high level of expression has a deleterious impact on the prognosis of BLCA patients. This strongly shows that ISCA1 is a significant prognostic factor for BLCA and that it could be used as a new prognostic detection target and treatment approach.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Systematic pan-cancer analysis identified neuropilin 1 as an immunological and prognostic biomarker
    Ma, Xiao
    Zhao, Yang
    Shi, Congcong
    Jiang, Hong
    Liu, Haonan
    Wang, Hongmei
    Qin, Xiaobing
    Wang, Yuqin
    Han, Zhengxiang
    CELL BIOCHEMISTRY AND FUNCTION, 2023, 41 (06) : 658 - 675
  • [42] RAC1 as a potential pan-cancer diagnostic, prognostic, and immunological biomarker
    Tao, Linglong
    Xu, Xiaoyu
    Fang, Zhengxuying
    Christopoulos, Petros
    Cortinovis, Diego
    Lu, Yi
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (03) : 1533 - 1553
  • [43] IDENTIFICATION OF ISYNA1 AS A POTENTIAL PROGNOSTIC BIOMARKER FOR RENAL CANCER
    Koguchi, Tomoyuki
    Matsuoka, Kanako
    Hata, Junya
    Sato, Yuichi
    Akaihata, Hidenori
    Kataoka, Masao
    Ogawa, Soichiro
    Haga, Nobuhiro
    Kushida, Nobuhiro
    Ishibashi, Kei
    Ikawa, Ken
    Kojima, Yoshiyuki
    JOURNAL OF UROLOGY, 2017, 197 (04): : E498 - E498
  • [44] Bladder Cancer-associated Protein, a Potential Prognostic Biomarker in Human Bladder Cancer
    Moreira, Jose M. A.
    Ohlsson, Gita
    Gromov, Pavel
    Simon, Ronald
    Sauter, Guido
    Celis, Julio E.
    Gromova, Irina
    MOLECULAR & CELLULAR PROTEOMICS, 2010, 9 (01) : 161 - 177
  • [45] SLITRK2 as a prognostic and immunological biomarker in gastric cancer
    Zhu, Huiqiong
    Xiong, Hailin
    Guo, Xuli
    Liao, Haojie
    Zhang, Shuyi
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [46] Identification of a Novel Ferroptosis-Related Gene Prognostic Signature in Bladder Cancer
    Sun, Jiale
    Yue, Wenchang
    You, Jiawei
    Wei, Xuedong
    Huang, Yuhua
    Ling, Zhixin
    Hou, Jianquan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [47] Identification of ALYREF in pan cancer as a novel cancer prognostic biomarker and potential regulatory mechanism in gastric cancer
    Yujie Yuan
    Yiyang Fan
    Wenqing Tang
    Hui Sun
    Jinghan Sun
    Hongmeng Su
    Hong Fan
    Scientific Reports, 14
  • [48] Identification of ALYREF in pan cancer as a novel cancer prognostic biomarker and potential regulatory mechanism in gastric cancer
    Yuan, Yujie
    Fan, Yiyang
    Tang, Wenqing
    Sun, Hui
    Sun, Jinghan
    Su, Hongmeng
    Fan, Hong
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [49] A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer
    Piao, Xuan-Mei
    Jeong, Pildu
    Yan, Chunri
    Kim, Ye-Hwan
    Byun, Young Joon
    Xu, Yanjie
    Kang, Ho Won
    Seo, Sung Phil
    Kim, Won Tae
    Lee, Jong-Young
    Kim, Isaac Y.
    Moon, Sung-Kwon
    Choi, Yung Hyun
    Cha, Eun-Jong
    Yun, Seok Joong
    Kim, Wun-Jae
    ONCOLOGY LETTERS, 2020, 19 (01) : 476 - 486
  • [50] Immunological significance of alternative splicing prognostic signatures for bladder cancer
    Li, Xinyun
    Yang, Lin
    Huang, Wei
    Jia, Bo
    Lai, Yu
    HELIYON, 2022, 8 (02)